Apexigen, Inc.

Epitomics, Inc.

Jiangsu Simcere Pharmaceutical R&d Co., Ltd

Jiangsu Simcere Pharmaceutical Co., Ltd

Weimin Zhu

Guo-Liang Yu

Yaohuang Ke

Yongke Zhang

Robert Pytela

Qi Qian

Harry C Au

Luc Adam

Sum Wai Pierre Lee

Xiaodong Yang

Karin Vroom

Xin Fan

Liang Xiang

Pierre Li

Guoliang Yu

Li Wei

Fanxin Ma

The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.

Anti-CD40 antibodies

Provided herein, inter alia, is a method for producing an enriched population of antigen-specific plasma cells. In some embodiments, the method may comprise: (a) obtaining a sample of cells from an animal that has been immunized by an antigen, wherein the sample comprises B cells; (b) enriching for a population of antigen-specific B cells that comprise cell surface antibodies that are specific for the antigen by: i. contacting at least 105 of the cells in said sample, en masse, with the antigen or a portion thereof; and ii. isolating cells that bind to the antigen or portion thereof; and (c) activating the enriched B cells, en masse, in the presence of the antigen or portion thereof, to produce the enriched population of antigen-specific plasma cells.

High throughput monoclonal antibody generation by B cell panning and proliferation

The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Fusion partner for production of monoclonal rabbit antibodies

The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.

Anti-RANKL antibodies and methods of use

Anti-CD40 antibodies and methods of use

The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.

Anti-KDR antibodies and methods of use

Methods of inhibiting proliferation of CD40-expressing cancer cells with anti-CD40 antibodies

The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.

Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody

Polynucleotides encoding anti-CD40 antibodies

An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target.

Anti-VEGF antibody

Growing community of inventors

San Francisco, CA, United States of America

Weimin Zhu